Philips Posts Strong Q4 2025, Lifts Margins and Cash Flow as It Sets 2026–2028 Growth Targets
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Koninklijke Philips ( (PHG) ) has provided an announcement.
Philips reported its full-year and fourth-quarter 2025 results on February 10, 2026, showing a 6% rise in comparable order intake for the year and 7% in the fourth quarter, with 2025 group sales of EUR 17.8 billion and 2% comparable sales growth, accelerating to 7% in the final quarter. Income from operations reached EUR 1,424 million for 2025, while the adjusted EBITA margin expanded by 80 basis points to 12.3% for the year and 160 basis points to 15.1% in Q4, supported by productivity gains that offset higher tariffs and underpinned solid cash generation.
Free cash flow for 2025 came in at EUR 512 million, including a EUR 1,025 million payment related to Respironics recall settlements in the U.S., while Q4 free cash flow surged to EUR 1,200 million, contributing to what management called a robust balance sheet. All main segments grew in the fourth quarter, with Connected Care and Personal Health delivering notable sales and margin improvements and Diagnosis & Treatment stabilizing margins despite tariff pressure, as Philips completed a three-year EUR 2.5 billion productivity program.
Operationally, Philips highlighted strong momentum in innovation and strategic partnerships, including the launch of helium-free 3.0T MR and AI-powered imaging platforms, new enterprise-scale patient monitoring solutions, and the acquisition of SpectraWAVE, signed in December 2025 and closed in January 2026, which broadens its coronary intervention portfolio. New long-term agreements with large U.S. healthcare providers for monitoring and cloud-based imaging IT, along with locally tailored consumer health launches in China, underscore Philips’ push to deepen its presence in key markets and support AI-enabled clinical workflows.
At its Capital Markets Day, Philips set 2026–2028 financial targets, aiming for a mid-single-digit comparable sales CAGR and a mid-teens adjusted EBITA margin by 2028, anchored in segment-specific growth strategies, innovation-led expansion, and continued disciplined execution. The company also proposed a 2025 dividend of EUR 0.85 per share and introduced updated 2030 impact ambitions, signaling to investors a focus on profitable growth, sustained productivity, and integrated sustainability goals after a three-year period of operational strengthening and quality remediation.
The most recent analyst rating on (PHG) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Koninklijke Philips stock, see the PHG Stock Forecast page.
Spark’s Take on PHG Stock
According to Spark, TipRanks’ AI Analyst, PHG is a Neutral.
Koninklijke Philips faces significant financial challenges with declining revenues and net losses, impacting its valuation negatively. However, strong order intake growth and improvements in EBITDA margin and cash flow from the earnings call provide a balanced outlook. Technical indicators suggest a bearish trend, adding to the cautious sentiment.
To see Spark’s full report on PHG stock, click here.
More about Koninklijke Philips
Koninklijke Philips N.V., or Royal Philips, is a Netherlands-based health technology company focused on diagnostic imaging, image-guided therapy, patient monitoring, and connected care solutions, alongside personal health products such as oral care and grooming devices. The group targets hospitals, health systems, and consumers globally, with a growing emphasis on data- and AI-driven, platform-based innovations in healthcare and self-care markets.
Average Trading Volume: 707,357
Technical Sentiment Signal: Buy
Current Market Cap: $28.06B
For an in-depth examination of PHG stock, go to TipRanks’ Overview page.
